

Certificate of Electronic Filing

I hereby certify that this correspondence is electronically filed with the United States Patent and Trademark Office via USPTO EFS Web

on: February 21, 2008

By: 

Margaret A. Powers

Attorney Docket No: 0228us410

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Poul Baad Rasmussen, *et al.*

Application No.: 10/609,296

Filed: June 27, 2003

For: Interferon Beta-Like Molecules

Examiner: Seharaseyon, Jegathesan

Art Unit: 1647

Confirmation No. 5764

**REQUEST FOR CORRECTED
FILING RECEIPT**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Mail Stop: Amendment

Dear Sir:

Attached is a marked-up copy of the Official Filing Receipt received from the Patent and Trademark Office in the above-identified patent application for which issuance of a corrected filing receipt is respectfully requested.

Specifically, Applicants request that the following corrections be made, as shown on the enclosed marked-up copy of the Official Filing Receipt:

- (1) As shown on the enclosed copy of a Petition to Correct Inventorship, the inventorship of the application has been corrected. Accordingly, please delete Joern Drustrup, Anders Hjelholt Pedersen, and Hans Thalsgard Schambye as inventors of the application on the Filing Receipt.

(2) The priority claim in the specification has been amended, as indicated in the accompanying Amendment, to specify that:


This application is a Continuation of US Application Serial No. 10/084,706 filed February 26, 2002, now U.S. Patent No. 7,144,574, which claims priority from and benefit of U.S. Provisional Application No. 60/272,116 filed February 27, 2001, U.S. Provisional Application No. 60/343,436 filed December 21, 2001, U.S. Provisional Application No. 60/302,140 filed June 29, 2001, U.S. Provisional Application No. 60/316,170 filed August 30, 2001, and U.S. Provisional Application No. 60/357,945 filed February 19, 2002. Pursuant to 35 U.S.C. §119(a)-(d), USSN 10/084,706 also claims priority from and benefit of Danish Patent Application No. PA 2001 00333 filed March 1, 2001.

Accordingly, please amend the priority claim as indicated on the attached marked-up copy of the Official Filing Receipt.

(3) Assignee Maxygen Holdings Ltd. has assigned all interest in the application to co-assignee Maxygen ApS. The Assignment document was recorded at Reel/Frame 016907/0166. Maxygen ApS is now the sole assignee of the application. Accordingly, please delete Maxygen Holdings Ltd. as assignee on the Official Filing Receipt.

Applicants believe that no fee is due in connection with this Request. However, in the event that a fee is due, please charge Deposit Account No. 50-0990. Please credit any overpayment to Deposit Account No. 50-0990.

Respectfully submitted,



Margaret A. Powers
Reg. No. 39,804

February 21, 2008
Maxygen, Inc.
Intellectual Property Department
515 Galveston Drive
Redwood City, CA 94063
Telephone: 650-298-5809
Facsimile: 650-298-5446
Customer No. 30560



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/609,296	06/27/2003	1646	1002	0228us420	3	34	2

30560
 MAXYGEN, INC.
 INTELLECTUAL PROPERTY DEPARTMENT
 515 GALVESTON DRIVE
 RED WOOD CITY, CA 94063

CONFIRMATION NO. 5764

CORRECTED FILING RECEIPT



TOC000000011358299*

COPY

Date Mailed: 11/26/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Poul Baad Rasmussen, Soeberg, DENMARK;
 Joern Drstrup, Farum, DENMARK;
 Grethe Rasmussen, Farum, DENMARK;
 Anders Hjelholt Pedersen, Lyngby, DENMARK;
 Hans Thalsgard Schambye, Frederiksberg C., DENMARK;
 Kim Vilbour Andersen, Broenshoej, DENMARK;
 Claus Bornaes, Hellerup, DENMARK;

Assignment For Published Patent Application

Maxygen ApS;
 Maxygen Holdings Ltd.;

Domestic Priority data as claimed by applicant

This application is a CON of 10/084,706 02/26/2002
 which claims benefit of 60/272,116 02/27/2001
 and claims benefit of 60/343,436 12/21/2001
 and claims benefit of 60/302,140 06/29/2001
 and claims benefit of 60/316,170 08/30/2001
 and claims benefit of 60/357,945 02/19/2002

PAT 7,144,574

Foreign Applications

DENMARK PA 2001 00333 03/01/2001
 DENMARK PA 1999-01197 08/27/1999
 DENMARK PA 1999-01691 11/26/1999

 DENMARK PA 2000 00194 02/07/2000.

If Required, Foreign Filing License Granted: 10/14/2003

Projected Publication Date: 01/22/2004

Non-Publication Request: No

Early Publication Request: No

Title

Interferon beta-like molecules

Preliminary Class

424

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).